Company Profile
|

Welcome to PARI Pharma!

The future of effective aerosol therapies lies in the optimization of drug-to-device and device-to-drug. PARI Pharma has taken the next step and combined formulation development, next generation aerosol platforms, and aerosol characterization under one roof.

We are currently working with both the eFlow® Technology (lower respiratory) and Vibrent® Technology (upper respiratory) Advanced Aerosol Delivery platforms.

This multifunctional development program is the key to creating targeted therapies with high deposition amounts, low side-effect profiles, improved patient compliance…and better controlled, healthier patients.

After 100 years, we know aerosol science and aerosol delivery.

News
June 20, 2011 |

On Track to Report Data from Completed Trial in Mid-2012

more
June 20, 2011 |

Monmouth Junction, NJ. - June 10, 2011 - Insmed Incorporated (Nasdaq CM: INSM),...

more
June 13, 2011 |

SAN FRANCISCO, Jan. 10, 2011 -- /PRNewswire/ -- Mpex Pharmaceuticals, Inc....

more